These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29609511)

  • 1. Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience.
    Coons JC; Miller T
    Ther Adv Respir Dis; 2018; 12():1753466618766490. PubMed ID: 29609511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.
    Bourge RC; Tapson VF; Safdar Z; Benza RL; Channick RN; Rosenzweig EB; Shapiro S; White RJ; McSwain CS; Gotzkowsky SK; Nelsen AC; Rubin LJ
    Cardiovasc Ther; 2013 Feb; 31(1):38-44. PubMed ID: 22970909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    LeVarge BL; Channick RN
    Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treprostinil for the treatment of pulmonary arterial hypertension.
    Torres F; Rubin LJ
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
    Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
    Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral treprostinil for the treatment of pulmonary arterial hypertension.
    de Lartigue J
    Drugs Today (Barc); 2014 Aug; 50(8):557-65. PubMed ID: 25187906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inpatient Initiation of Oral Treprostinil in an Academic Medical System.
    Hohlfelder B; Tonelli AR; Heresi GA; Bair N; Rahaghi FF; Bauer SR
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):547-553. PubMed ID: 32424651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series.
    Ackerbauer KA; Tandon R
    J Pharm Pract; 2018 Apr; 31(2):163-166. PubMed ID: 28464760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transitioning Parenteral or Inhaled Treprostinil to Oral Treprostinil Diolamine: Case Series and Review of the Literature.
    Smith ZR; Kelly B; Awdish RL; Hegab S
    J Pharm Pract; 2019 Oct; 32(5):599-604. PubMed ID: 29558853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus.
    Brewer J; Wilson M; Coons JC; Schmit A; Whittenhall ME; Kimber A; Broderick M; Lee D; Patzlaff N; Miller C; Ataya A; LaRoy V; King CS; Ravichandran AK; Kingrey JF; Sahay S
    Respir Med; 2024 Sep; 231():107734. PubMed ID: 38986791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension.
    White RJ; Torres F; Allen R; Jerjes C; Pulido T; Yehle D; Howell M; Laliberte K; Marier JF; Tapson VF
    J Cardiovasc Pharmacol; 2013 Jun; 61(6):474-81. PubMed ID: 23328389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
    J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of treprostinil in the management of pulmonary hypertension.
    Skoro-Sajer N; Lang I
    Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of a pharmacokinetic interaction between treprostinil diolamine and sildenafil in healthy adult volunteers.
    Gotzkowsky SK; Kumar P; Mottola D; Laliberte K
    J Cardiovasc Pharmacol; 2013 May; 61(5):444-51. PubMed ID: 23429588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration.
    Kumar P; Thudium E; Laliberte K; Zaccardelli D; Nelsen A
    Clin Pharmacokinet; 2016 Dec; 55(12):1495-1505. PubMed ID: 27286723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers.
    Jones A; Wang-Smith L; Pham T; Laliberte K
    J Cardiovasc Pharmacol; 2014 Mar; 63(3):227-32. PubMed ID: 24603117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Treprostinil in Pediatric Pulmonary Hypertension: Case Reports and Review of the Literature.
    Gavotto A; Thomas F; Werner O; Moreau J; Amedro P
    J Cardiovasc Pharmacol; 2020 Jul; 76(1):23-31. PubMed ID: 32168152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
    Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
    Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.